How should transfusion be performed in cold agglutinin disease?

Transfusion in Cold Agglutinin Disease

In cold agglutinin disease (CAD), transfuse only when absolutely necessary using a restrictive hemoglobin threshold of ≤7–8 g/dL, and always administer blood through a blood warmer with the patient kept warm to prevent exacerbation of complement-mediated hemolysis. 1, 2

Key Principle: Transfusion Can Worsen Hemolysis

• Transfusion itself can trigger or exacerbate cold agglutinin-mediated hemolysis, making the decision to transfuse particularly critical in CAD. 3
• Cold agglutinins cause complement activation and hemolysis when red blood cells are exposed to temperatures below body temperature, which occurs during standard blood transfusion. 3, 4
• Many CAD patients can be managed without transfusion even with significant anemia, as their condition may stabilize with treatment of the underlying disease and avoidance of cold exposure. 1

When to Transfuse: Apply Restrictive Thresholds

• Use a hemoglobin threshold of ≤7–8 g/dL for transfusion decisions in hemodynamically stable CAD patients, consistent with general restrictive transfusion guidelines. 5
• Transfuse at ≤8 g/dL or when symptomatic if the patient has pre-existing cardiovascular disease (chest pain, orthostatic hypotension, tachycardia unresponsive to fluids, or worsening heart failure). 5
• Avoid liberal transfusion strategies; the restrictive approach does not increase mortality, cardiac events, or infection risk in stable patients. 5

Mandatory Pre-Transfusion Preparation

Blood Bank Workup

• Perform extensive serologic testing to resolve blood group discrepancies caused by cold agglutinins, which commonly produce type IV discrepancies during routine blood typing. 1, 2
• Wash red blood cells with warm saline (37°C) to remove cold agglutinins and prevent in vitro agglutination during compatibility testing. 1, 2
• Absorb autoantibodies at 4°C using washed RBCs to identify any underlying alloantibodies that may be masked by the cold agglutinin. 1
• Perform crossmatching with pre-warmed serum (37°C) to ensure compatibility and avoid false-positive reactions. 2
• Extensive phenotyping of red cell antigens should be performed to detect any alloantibodies, as these patients may have both autoantibodies and alloantibodies. 6

Clinical Preparation

• Assess cold agglutinin titer: Titers ≥1:64 at 4°C confirm clinically significant CAD and predict higher risk of transfusion-related hemolysis. 4, 2
• Verify Direct Antiglobulin Test (DAT): Nearly all CAD cases show positive C3d DAT; a negative C3d DAT should prompt investigation for warm AIHA instead. 4
• Note that DAT can be falsely negative in some cases despite active hemolysis, complicating diagnosis. 3

Transfusion Administration Protocol

Warming Requirements (Critical)

• Always use a blood warmer during transfusion to maintain blood temperature at 37°C throughout the infusion. 2
• Keep the patient warm by covering with blankets and maintaining a warm room temperature to prevent cold-induced hemolysis. 2, 7
• Warm the venous return lines and any extracorporeal circulation equipment if applicable. 7
• Transfuse slowly to allow monitoring for signs of hemolysis and to maintain adequate warming. 2

Monitoring During Transfusion

• Watch for signs of hemolytic transfusion reaction: fever, chills, back pain, dark urine, hemoglobinuria, and worsening anemia. 3
• Monitor hemoglobin levels closely after transfusion, as hemolysis may cause a rapid drop without compensatory reticulocytosis during aplastic phases. 8
• Consider performing an infusion test with a small aliquot of blood prior to full transfusion in high-risk cases to confirm tolerability. 8

Special Considerations

Transfusion in Acute Hemolytic Crisis

• Transfusion is indicated for hemorrhagic shock or acute hemorrhage with hemodynamic instability, even in CAD. 5
• Ensure adequate hydration during hemolytic crises to support renal function and prevent acute kidney injury from hemoglobinuria. 9
• Administer single units and reassess before giving additional transfusions, rather than transfusing multiple units at once. 5

When Transfusion May Be Avoided

• Patients with cold agglutinin titers of 1:1024 may stabilize without transfusion if hemodynamically stable and asymptomatic, even with significant anemia. 1
• Treat the underlying cause: Secondary CAD associated with lymphoproliferative disorders or infections may improve with treatment of the primary disease. 4, 6
• Consider complement inhibition (sutimlimab) or rituximab-based therapy as alternatives to transfusion in chronic CAD with symptomatic anemia. 9, 10

Common Pitfalls to Avoid

• Do not transfuse cold blood: Standard refrigerated blood will exacerbate hemolysis; warming is non-negotiable. 2
• Do not assume transfusion will improve oxygen delivery: In CAD, transfused cells may hemolyze rapidly, providing minimal benefit while worsening the clinical picture. 3
• Do not overlook alloantibodies: Cold agglutinins can mask clinically significant alloantibodies during compatibility testing, leading to delayed hemolytic transfusion reactions. 6
• Do not use corticosteroids as primary therapy for CAD; they are ineffective in cold agglutinin-mediated hemolysis, unlike warm AIHA. 4, 6
• Do not perform procedures at room temperature: Even apheresis, stem cell collection, or plasma exchange must be conducted with strict temperature control to prevent agglutination. 7, 8

Biological Compatibility Testing

• Test for biological compatibility in addition to serologic compatibility, particularly in refractory cases where standard testing may not predict in vivo hemolysis. 6
• Hemolysis parameters (LDH, indirect bilirubin, haptoglobin) should be monitored before and after transfusion to assess the hemolytic response. 9